Loading
Latest filing published 14 Feb 2025 for X4 Pharmaceuticals, Inc. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Mary DiBiase (senior executive) discloses dealings in X4 Pharmaceuticals, Inc to SEC (Form 4). Between 8 September 2021 and 12 February 2025, the trades on record add up to 21 filings.
Sales make up the whole of the open-market record (15 sales, €90k). The amount is not disclosed for 5 filings. The rest of the record consists of 6 share grants.
The latest filing, published on 14 February 2025, reports a share grant in X4 Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations